The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The use of magrolimab plus rituximab in R/R indolent NHL
Mark Roschewski, MD, NCI Center for Cancer Research, Bethesda, MD, discusses the use of magrolimab combined with rituximab in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (NHL). The findings of this study indicate that over 40% of patients achieve complete responses (CRs), with some being durable responses, highlighting the potential of this pathway in developing new treatments for B-cell lymphomas. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
